BioWorld

Dec. 15, 2008

View Archived Issues

Exelixis Getting $195M Up Front in BMS Cancer Collaboration

Exelixis signed a major deal with Bristol-Myers Squibb Co., in which the drugmaker would pay a hefty $195 million up front for rights to cancer programs developed by Exelixis. (BioWorld Today) Read More

Daschle to Lead HHS, White House Health Reform Office

Read More

Momenta's Offering Adds $25M as FOBs Gain Momentum

Read More

BioPartnering: Learn How to Make the Right Moves

Read More

Vivus' Avanafil Starts Pivotal Testing in Erectile Dysfunction

Read More

Disappointing Memory Data Send Lexicon Shares Sliding

Read More

Other News To Note

Read More

Clinic Roundup

Read More

CTRC-AACR Roundup

Read More